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 Abstract                                                                                                            
Background: The ability of tumour suppressor protein p53 (P53) to 
regulate cell cycle processes can be modulated by hepatitis B virus 
(HBV). While preliminary evidences indicates the involvement of 
protein-x of HBV (HBx) in altering p53 DNA binding, no further 
data have been accumulated for the significance of serum p53 in 
chronic hepatitis B virus infected patients. 
Methods: 72 non-cirrhotic and 19 cirrhotic patients infected 
by HBV were enrolled for the analysis in this study. Enzyme 
linked immunosorbent assay (ELISA) was performed to study 
the concentrations of serum p53 protein. The tertiary structures 
of HBx and P53 were docked by Z-dock and Hex servers for 
in-silico protein-protein interaction analysis. 
Results: There was a significant association between the 
serum p53 and cirrhosis (OR=1.81 95% CI: 1.017-3.2, P=0.044). 
Cirrhotic patients had higher level of serum p53 compare with 
chronic infection of HBV (1.98±1.22 vs. 1.29±0.72 U/ml, P=0.05). 
No evidence of correlation was seen between the different 
variables such as age, gender, log viral load, serum alkaline 
phosphatase (ALP) and alanine aminotransferase (ALT) with 
serum p53. Tertiary model shows that the amino acid residues 
from Arg110 to Lys132 of the N-terminal of P53 which is critical 
for ubiquitination, are bonded to a region in N- terminal of HBx 
amino acid residues from Arg19 to Ser33. 
Conclusion: There is an increase in serum p53 in HBV-related 
cirrhosis patients. In this case, HBx might be responsible for such 
higher concentration of p53 through HBx-p53 protein-protein 
interaction, as is shown by molecular modeling approach.
Please cite this article as: Shahnazari P, Sayehmiri K, Minuchehr Z, Parhizkar A, 
Poustchi H, Montazeri G, Mohamadkhani A. The Increased Level of Serum p53 
in Hepatitis B-Associated Liver Cirrhosis. Iran J Med Sci. 2014;39(5):446-451.
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 Introduction                                                                                         
The infection of hepatitis B virus is one of the most frequent causes 
of chronic liver disease, though the principal molecular mechanisms 
responsible for its clinical outcome have not been well characterized.1,2 
In response to stress signal, induced by viral components, p53 
selectively regulates a set of its target genes to employ its function 
in tumor suppression.3 It is well known that this protein regulates 
the cell cycle pathways as part of its vital function to keep the 
genomic stability.4-6 Therefore, p53 prevents the perpetuation of 
a defective genome and the development of cancer. Remarkably, 
current studies have focused on the impact of p53 to transactivate 
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genes involved in aerobic metabolism.4 Mutations 
in p53 gene not only considerably drive disease 
progression, but also have been shown as a 
valuable tumor marker in most of the tumors.3,7,8 
High prevalence of p53 alterations have 
been investigated in HCC as a consequence 
of chronic hepatitis B.9,10 HBV encodes a small 
protein x (HBx) that seems to play a critical 
role in hepatocarcinogenesis and found to be 
expressed in chronic hepatitis, cirrhotic liver, and 
hepatocellular carcinoma (HCC).11,12 However, 
preliminary reports verify that the distal C-terminal 
region of HBx has inhibitory effect on apoptosis 
through inactivation of p53 in microinjected 
human fibroblasts.13,14 It has also been proposed 
that the interaction of HBx with DNA-bound p53 
induces a repression domain in HBx leading to 
inhibition of cellular transcription machinery.14 
The p53 protein is composed of 393 residues 
and is divisible into three structural domains. 
The amino-terminal trans-activation domain, 
the central ‘core’ domain (residues  from 102 to 
292) that is essential for sequence-specific DNA 
binding and the carboxyl terminus oligomerization 
domain, which is required for the assembly of 
p53 tetramers and contains nuclear localization 
signals.5 The interaction of HBx protein and p53 
tumor suppressor protein has been the subject 
of examinations in many researches in order to 
evaluate the biological function of p53 protein in 
HBV infected cells.14-16
In this study, the level of serum p53 in chronic 
hepatitis and cirrhotic patients following HBV 
infection is evaluated. Additionally, the interaction 
of p53 protein and protein x of HBV is predicted with 
computational modeling to clarify the excess level 
of p53 protein in HBV- related cirrhotic patients.
 Patients and Methods                                                                                        
Patients 
In a cross-sectional study, patients referred 
to the Hepatitis Clinic of Shariati Hospital 
during a period of six months were included. 
All patients were HBsAg positive and HBeAg 
negative. They were divided into two groups: (a) 
72 non-cirrhotic patients with normal or elevated 
ALT; (b) 19 patients with cirrhosis defined as 
the presence of ascites and/or oesophageal 
varices and/or splenomegaly, together with low 
serum albumin, prolonged prothrombin time 
and thrombocytopenia at enrolment. Patients 
with evidence of concomitant hepatitis C or D 
virus infection, HIV infection, autoimmune, drug-
induced or other causes of chronic liver disease 
were excluded. Serum samples and demographic 
data were collected at the initial assessment and 
stored at -70˚C prior to analysis. The protocol of 
this study was approved by the Ethics Committee 
of Digestive Disease Research Centre, Tehran 
University of Medical sciences. 
Clinical Evaluation and HBV-DNA Quantification
Serological markers were determined with a 
commercial ELISA kit (Dia.Pro diagnostic, Milano, 
Italy). The 91 positive serum samples of HBsAg 
were evaluated with respect to the presence of 
p53 protein using the ELISA method (Bender 
MedSystem, Vienna, Austria). HBV DNA was 
extracted from 200 ml of serum using the High 
Pure Viral Nucleic Acid Kit (Roche Germany) 
and then quantified in the Light-Cycler (Roche) 
by RealARTTM HBV LC PCR (QIAGEN, Hilden, 
Germany) according to the manufacturer’s 
instructions. The linear range of this assay is 
102–109 copies/ml.
Hbx and p53 Interaction Analysis
The sequence of protein-x of HBV was 
obtained by translation of the appropriate 
reading frame in complete viral genome of HBV 
genotype D consensus [UniProt: P0C681]. The 
tertiary structure of Hbx was used from previously 
gathered data.17 The X-ray crystal structure of 
P53 was retrieved from PDB (2OCJ). The protein-
protein interactions were achieved by means 
of Z-dock (http://zdock.umassmed.edu/)18 and 
HEX (http://hexserver.loria.fr).19 KFC2 (http://kfc.
mitchell-lab.org)20 was used for prediction binding 
“hot spots” within protein-protein interfaces by 
recognizing structural features. 
Statistical Analysis
All statistical analyses were performed with 
the Statistical Program for Social Sciences 
(SPSS, version 19 for Windows; SPSS Inc., 
Chicago, Ill.). The mean±standard deviation 
(SD) was considered for continuous variables. 
The associations between variables, age, P53, 
viral load, ALT and ALP were computed using 
the Pearson correlation coefficient (r). Normality 
of variables was checked using One-Sample 
Kolmogorov-Smirnov Test. The relationship 
between p53 concentrations and cirrhotic or 
non-cirrhotic patients was assessed using logistic 
regression techniques (after control for multiple 
covariates). In logistic regression models, both 
Enter and Likelihood forward conditional models 
were implemented. Statistical significance was 
defined by a P value of less than 0.05.
 Results                                                                                         
Demographic and Biochemical Characteristics
From 91 chronic hepatitis B patients with the 
mean±SD age of 44±13 years, 67 were male 
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(73%) and there was no significant difference 
in the cases of ALT, HBV DNA and serum p53 
among them. The serum levels of p53 showed no 
significant direct correlations with serum ALT and 
HBV DNA level. Also no significant correlation was 
observed between serum P53 and age, though 
the level of serum ALT had positive correlation 
with the copies/mL of HBV DNA (r=0.4, P=0.001). 
Patients’ Clinical Features 
Nineteen patients with the mean age of 
54±12 years old (a decade older than patients 
with chronic hepatitis B (54±12 vs. 42±12 years, 
P=0.001)) with complication of cirrhosis, showed 
higher serum p53 (1.98±1.22 vs 1.29±0.72 U/
mL; P=0.050). Following age adjustment, the 
p53 concentrations remained significantly high 
in cirrhotic patients (P=0.038). Serum p53 had 
a total mean of 1.32±0.94 U/mL, however in 
the cirrhotic patients, the number of individuals 
with the p53 more than 2 U/mL (36.8%) was 
not significantly greater than the non-cirrhotic 
patients (27.8%) (P=0.421). The characteristics of 
subjects in these distinct groups are summarized 
in table 1.
Association of Serum p53 Level with Cirrhosis
To analyze the presence of liver cirrhosis in 
CHB patients, several characteristics such as p53, 
age, gender, log viral load and serum ALT and ALP 
were selected in a multivariable-adjusted logistic 
regression model. As shown in table 2, there is a 
significant association between increased serum 
p53 and cirrhosis (OR=1.81 95% CI: 1.017-3.2, 
P=0.044). Additionally, no evidence of interactions 
and multicollinearity between variables (age, 
gender, log viral load, ALP and ALT) with liver 
cirrhosis was identified. Moreover, the association 
of serum level of p53 and age with cirrhosis using 
conditional likelihood forward method in logistic 
regression is estimated as:
agep
p
p 074.05358.9.5)
1
log( ++−=
−
This model shows that p53 and age are 
two independent predictive factors for the liver 
cirrhosis.
In Silico Analysis of p53 Interaction with HBx
The model of tertiary structure of HBx was 
docked with P53 using Z-dock and Hex servers. 
The best model was selected from the overlapped 
results and then analyzed with KFC2 server to 
find hot spots in protein-protein interactions. The 
data indicated that the residues from Arg110 to 
Lys132 in the N-terminal trans-activation domain 
(TAD) of P53 protein bonded to a region in the 
N- terminal of Hbx protein from Arg19 to Ser33 
(figure 1). 
KFC2 Server (predicted binding “hot spots” 
within protein-protein interfaces) showed Arg110, 
Leu111, Gly112, Phe113, His115, Tyr126, pro128, 
Table 1: Comparable clinical and pathological data of cirrhotic and non-cirrhotic patients
Clinical factor* All patients (n=91) Non-cirrhotic (n=72) Cirrhotic (n=19) P value
Age (Years) 44±13 42±12 54±12 0.001**
log HBV DNA (copies/mL) 3.63±0.94 3.55±0.93 3.92±0.92 0.1
ALT (IU/L) 61±43 60±47 65±30 0.6
ALP (IU/L) 217±80 209±76 246±90 0.6
P53 (U/mL) 1.32±0.94 1.29±0.72 1.98±1.22 0.050**
*Mean±SD; **P value refers to differences between the 5 groups
Table 2: Two models to predict cirrhosis, in multivariate logistic model age and p53 were associated with liver cirrhosis. Using 
conditional likelihood forward method in logistic regression as model 2, shows age and p53 are associated with liver cirrhosis 
independently
Table 2 B S.E. Wald Sig. OR 95% CI. for OR
Lower Upper
Model 1
Age 0.066 0.025 6.948 0.008 1.068 1.017 1.122
Sex -0.105 0.687 0.023 0.879 0.901 0.234 3.465
ALT -0.002 0.007 0.101 0.751 0.998 0.983 1.012
ALP 0.005 0.004 1.400 0.237 1.005 0.997 1.013
Log_Viral_load 0.391 0.371 1.112 0.292 1.479 0.715 3.061
p53† 0.593 0.294 4.070 0.044 1.809 1.017 3.219
Constant -7.972 2.079 14.701 0.000 0.000
Model 2
Age 0.074 0.023 10.272 0.001 1.077 1.029 1.126
p53 0.584 0.281 4.324 0.038 1.793 1.034 3.108
Constant -5.939 1.352 19.290 0.000 0.003 Constant -5.939
CI=Confidence interval; OR=Odds ratio (OR significant [ie, P<0.05] indicated in bold); †Adjusted for the effect of p53 and 
cirrhosis (OR=1.81 95% CI: 1.017-3.2, P=0.044).
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Ala129 and Asp131 in P53 had high probability 
to interface with the Hbx protein. The hot spots 
of Hbx protein are: Arg19, Val21, Ala23, Glu24, 
Ser25, Cys26, Val30, and Ser33 which was 
compatible with the present docking data. 
 Discussion                                                                                        
This study describes the serum level of p53 protein 
in patients with chronic hepatitis B and HBV-related 
cirrhosis. The findings show that the concentrations 
of p53 in the serum of patients with HBV-related 
cirrhosis were significantly higher than its level 
in patients with chronic hepatitis B. However no 
significant correlation was noticed between the 
higher concentration of the p53 protein with age, 
gender and viral load. Furthermore, the docking 
results from protein-protein interaction exhibited that 
the N-terminal of HBx was bonded to the N-terminal 
trans-activation domain (TAD) in P53. 
The hypothesis that describes the higher 
p53 level in the serum of HBV-related cirrhotic 
patients might be the higher expression of HBx 
in cirrhotic patients as a consequence of viral 
replication or integration of viral genome in host 
genome during the end stage of liver disease, 
and also an increase of p53 protein half-life in its 
interaction with HBx. To clarify this hypothesis, 
it is mentioned that Mdm2 (Mouse double 
minute 2 homolog) which has been recognized 
as E3 ubiquitin-protein ligase, regulates both 
the transcriptional activity and the half-life of 
p53 in a negative feedback loop. This protein 
targets the N-terminal region of core domain of 
p53 protein for ubiquitin-mediated proteolysis.21 
In the other words, P53 turnover is regulated 
through mono- or poly-ubiquitination21,22 and HBx 
might interfere with the specific targeting of p53 
ubiquitination by Mdm2, therefore, increasing the 
half-life of p53. Thus the raised levels of serum 
p53 in cirrhotic patients support the hypothesis 
of HBx-p53 interaction. Although there is no 
significant correlation between HBV DNA level 
and serum p53 in the current findings, but HBx 
expression from integrated HBV DNA which is 
common in cirrhotic patients might be responsible 
for increased level of serum p53 through p53-
HBx protein-protein interaction.15,21 In this regard, 
increased expression of p53 in cirrhotic and HCC 
has already been reported.23
To date, there has been no precise or 
adequate research showing serum level of p53 
in chronic hepatitis B. However, there are some 
assessments about overexpression or unusual 
form of p53 protein in the serum.7,8 The unusual 
form of p53 has been associated with more half-
life of this protein and could expose an increase 
level of this protein in serum.3,7,24 The results of this 
study is consistent with a recent study of serum 
and cytoplasmic p53 concentrations in chronic 
hepatitis C, in which high level of the serum p53 
were detected in the patients with HCC and liver 
cirrhosis.23 In another study, Cheng et al. showed 
high expression of HBx in all cirrhosis samples by 
immunohistochemical staining.25 There are also 
some reports on close association between HBV 
infection and the progressive liver diseases with 
the abnormalities in p53 tumor suppressor.4,15
Although it is often believed that the p53 
is important in responding to DNA damage, 
oncogenic motivation and hypoxia; increased 
ability of p53 in regulating some features of 
Figure 1: Doking result of P53 and HBx. As shown, the HBx protein (in purple) from Arg19 to Ser33 is bonded to the amino acids 
Arg110 to Lys132 in N-terminal trans-activation domain (TAD) of P53 protein (in blue).                                                                               
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cellular metabolism in some disease development 
is now being revealed.26 Hence, the increased 
level of p53 in patients with advance liver disease 
underlines the importance of p53 in directing 
metabolic remodeling and metabolic disorders. 
This requires further investigation to determine 
the precise impact of p53 in interaction with viral 
products on HBV-related cirrhotic patients.
 Conclusion                                                                                         
This pilot study indicates a higher expression of 
serum p53 in cirrhotic infected patients with HBV. 
It presents a model for the interaction of p53 and 
HBx that indicates the role of HBx in cirrhosis 
patients for increasing p53 half-life. This is a matter 
for future investigations. Evaluation of p53 protein 
in serum samples could be a valuable tool for the 
assessment of HBV-related cirrhosis and chronic 
hepatitis B patients.
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